We report the case of a patient with rheumatoid arthritis who, after 2 months of treatment with etanercept, showed disseminated asymptomatic violaceous papules. Biopsy of the skin lesion showed chronic granulomatous dermatitis with negative staining for fungi and acid-fast bacilli (AFB). After discontinuation of etanercept, the patient's condition improved. Although apparently paradoxical, cases of cutaneous and systemic sarcoidosis after anti-TNF medications have been reported in the literature, with very few cases presenting exclusive cutaneous involvement.
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introduction
Sarcoidosis is a systemic granulomatous disease of unknown etiology. 1 It commonly affects the lungs, lymphoid system, and skin. 2 Diagnosis is based on clinical presentation and histopathological findings. 3 Tumor necrosis factor is produced by inflammatory cells such as macrophages, keratinocytes, and T helper 1 (Th1) lymphocytes. 4 It is implicated in the pathogenesis of granulomatous inflammatory diseases. Granuloma formation requires a Th1 pattern of response involving macrophages and CD4+ T lymphocytes activated with interferon (IFN) and IL-2 secretion, and macrophage activation causes increased production of tumor necrosis factor-alpha (TNF-α). There is a positive correlation between TNF-α levels and sarcoidotic disease activity. 3, 4 Thus, sarcoidosis would be effectively treated with TNF-α blockers. However, cases of cutaneous, pulmonary, and ocular sarcoidosis due to an unexpected and paradoxical effect of these medications have been reported. 3, 4 One of the hypotheses that have been reported is that the increased incidence of infections treated with anti-TNF-α could lead to the development of granulomas. 5 We report the case of a patient who developed sarcoidotic skin lesions during treatment with etanercept (ETN), without associated systemic manifestations. Similar cases reported in the literature are rare.
case report
A 62-year-old female patient diagnosed with rheumatoid arthritis for 13 years, treated with etanercept for 4 months. Two months after the beginning of this immunobiological treatment, violaceous papules appeared, which were asymptomatic, diffuse throughout the trunk and proximal areas of the limbs, and the face ( Figure 1 ). The patient reported fever coinciding with the onset of skin lesions, with no other associated symptoms. She denied comorbidities or the use of further medication. Histopathological examination of a lesion on the left shoulder revealed chronic granulomatous dermatitis (Figure 2 ). Staining for fungi and acid-fast bacilli yielded negative results. Blood count, lipid profile, blood glucose, renal and liver function were normal. A chest tomography was requested, but showed no signs of granulomatous disease. Tuberculin skin test was negative. We chose to switch from etanercept to abatacept, with progressive improvement in a few weeks until complete clearance of the lesion. The patient is still being monitored at the dermatology and rheumatology outpatient clinics, and she did not develop new lesions 8 months after etanercept discontinuation. The current treatment is done with prednisone and abatacept.
discussion and conclusion
The observation of granulomatous disease during treatment with TNF-α blocking agents seems paradoxical. However, the temporal relationship between beginning of therapy/onset of disease and regression of lesions after discontinuation of treatment strongly suggests that the TNF-α blocker is involved with the development of a granuloma. 6 Based on the clinical history, histopathology, and chronological sequence of events, our case report suggests the diagnosis of ETN-induced sarcoidosis.
Cases of sarcoidosis have been reported in the literature after use of TNF-α blockers. The use of anti-TNF agents would result in increased T lymphocyte reactivity and imbalance of cytokines, altering the homeostasis of the immune system responsible for the formation and maintenance of granuloma. 7, 8 Diagnosis remains a challenge probably because the safety profile of TNF-α blockers is mainly directed to infections. This should be taken into account in case of lung symptoms and negative cultures. Angiotensin converting enzyme has a good sensitivity (90%) and may help in the diagnosis. 9 In a systematic review, we observed that more cases of sarcoidosis have been reported as a consequence of therapy with ETN (soluble TNF-α fusion protein), compared with other TNF-α inhibitors such as infliximab (IFX) and adalimumab (ADA). This could be related to the different binding characteristics of each of the three TNF-α inhibitors (ETN, IFX, and ADA), since they present different clearances and binding avidities. 4 ETN is a fusion protein that primarily neutralizes soluble TNF-α, with reduced binding activity to membrane TNF-α compared with IFX. 6, 10 Given that TNF-α is only partially neutralized by ETN, there may be a redistribution of bioavailable cytokines that travel to low concentration sites such as the lungs. A new stimulus could thus result in the formation of granulomas. 6 In the literature review, to date, we have found only nine reported cases of sarcoidosis induced by TNF-α blockers, whose clinical presentation was exclusively cutaneous. The period between beginning of treatment and the onset of sarcoidosis ranged from 1 to 60 months. Cutaneous manifestations included papular eruptions, nodular eruptions (including facial nodules), scar lesions, and erythema nodosum. The non-cutaneous clinical manifestations reported included constitutional symptoms, hilar lymphadenopathy, pulmonary interstitial infiltrate, pulmonary nodules and micronodules, pleural effusion, uveitis, and hepatic involvement. Most cases involved organs other than the skin. 4 In most cases, there was regression after discontinuation of anti-TNF-α therapy, with an average time of 4, 6 and 8 months for IFX, ADA, and ETN, respectively.
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Thus, ETN may trigger cutaneous and/or systemic sarcoidosis, so that cutaneous manifestation may be the first or only manifestation of the disease. Physicians should be aware of this potential cutaneous and/or systemic adverse effect for early diagnosis and initiation of the appropriate therapy for each patient. 4 resuMo Desenvolvimento de sarcoidose exclusivamente cutânea em paciente com artrite reumatoide, durante tratamento com etanercepte Relata-se caso de uma paciente com artrite reumatoide que, após 2 meses de tratamento com o medicamento imunobiológico anti-TNF-α etanercepte, apresentou quadro cutâneo compatível com sarcoidose. Notavam-se pápulas violáceas disseminadas e assintomáticas, cuja histopatologia revelou dermatite crônica granulomatosa, com pesquisa de fungos e bacilos álcool-ácido resistentes negativa. Após suspensão do etanercepte, houve regressão do quadro cutâneo. Apesar de paradoxal, têm sido relatados na literatura casos de sarcoidose cutânea e sistêmi-ca após uso de medicações anti-TNF, sendo raríssimos os casos com acometimento cutâneo exclusivo.
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